Naltrexone and Alzheimer's disease

Roles of β-Endorphin in Stress, Behavior, Neuroinflammation, and Brain Energy Metabolism

“…A second study in 1986 also found no cognitive benefit to the administration of opioid antagonist naloxone, though increases in behavioral arousal and psychomotor retardation at higher doses were noted [ 242 ]. Other studies examining the use of opioid antagonists find similar inefficacy [ 243 , 244 ]. While these studies did not investigate long-term β-endorphin inhibition, the application of opioid antagonists to benefit patients of neurodegenerative disease appears to be limited.…”

Roles of β-Endorphin in Stress, Behavior, Neuroinflammation, and Brain Energy Metabolism

“…A second study in 1986 also found no cognitive benefit to the administration of opioid antagonist naloxone, though increases in behavioral arousal and psychomotor retardation at higher doses were noted [ 242 ]. Other studies examining the use of opioid antagonists find similar inefficacy [ 243 , 244 ]. While these studies did not investigate long-term β-endorphin inhibition, the application of opioid antagonists to benefit patients of neurodegenerative disease appears to be limited.…”

A GPCR/secretase complex regulates β- and γ-secretase specificity for Aβ production and contributes to AD pathogenesis

“…In 1980s, there were several double-blinded placebocontrolled clinical studies showing that the nonselective antagonists of opioid receptors, including naloxone and naltrexone, fail to affect overall cognitive functioning in individuals with probable AD [30][31][32]. However, these studies could not rule out the possibility that selective antagonist of opioid receptors might be efficacious in AD treatment, as DOR, MOR and KOR might play different roles in AD pathology.…”

Pharmacotherapy and the neurobehavioural sequelae of traumatic brain injury

“……”

Roles of β-Endorphin in Stress, Behavior, Neuroinflammation, and Brain Energy Metabolism

“…A second study in 1986 also found no cognitive benefit to the administration of opioid antagonist naloxone, though increases in behavioral arousal and psychomotor retardation at higher doses were noted [ 242 ]. Other studies examining the use of opioid antagonists find similar inefficacy [ 243 , 244 ]. While these studies did not investigate long-term β-endorphin inhibition, the application of opioid antagonists to benefit patients of neurodegenerative disease appears to be limited.…”

A GPCR/secretase complex regulates β- and γ-secretase specificity for Aβ production and contributes to AD pathogenesis

“…In 1980s, there were several double-blinded placebocontrolled clinical studies showing that the nonselective antagonists of opioid receptors, including naloxone and naltrexone, fail to affect overall cognitive functioning in individuals with probable AD [30][31][32]. However, these studies could not rule out the possibility that selective antagonist of opioid receptors might be efficacious in AD treatment, as DOR, MOR and KOR might play different roles in AD pathology.…”

Pharmacotherapy and the neurobehavioural sequelae of traumatic brain injury

“……”

Roles of β-Endorphin in Stress, Behavior, Neuroinflammation, and Brain Energy Metabolism

“…A second study in 1986 also found no cognitive benefit to the administration of opioid antagonist naloxone, though increases in behavioral arousal and psychomotor retardation at higher doses were noted [ 242 ]. Other studies examining the use of opioid antagonists find similar inefficacy [ 243 , 244 ]. While these studies did not investigate long-term β-endorphin inhibition, the application of opioid antagonists to benefit patients of neurodegenerative disease appears to be limited.…”

A GPCR/secretase complex regulates β- and γ-secretase specificity for Aβ production and contributes to AD pathogenesis

“…In 1980s, there were several double-blinded placebocontrolled clinical studies showing that the nonselective antagonists of opioid receptors, including naloxone and naltrexone, fail to affect overall cognitive functioning in individuals with probable AD [30][31][32]. However, these studies could not rule out the possibility that selective antagonist of opioid receptors might be efficacious in AD treatment, as DOR, MOR and KOR might play different roles in AD pathology.…”

Pharmacotherapy and the neurobehavioural sequelae of traumatic brain injury

“……”